Epidemiology

Medical Breakthroughs Reliant on Better Clinical Trials

Retrieved on: 
Tuesday, November 7, 2023
EDC, FDA, SMS, Epidemiology, American Opportunity Tax Credit, Health, Rare, Family, Registry, Prevalence, Televisit, Research, Roger Hawkins (drummer), Friends, Artificial intelligence, Clinical data management, Transport, George Mason University, Clinical trial, Informatics, The New England Journal of Medicine, Travel, Developing country, Sponsor, Diversity, EHR, Safety, Patient, Bias, Pharmaceutical industry, Birth control, Access, AI

MANASSAS, Va. , Nov. 7, 2023 /PRNewswire-PRWeb/ -- The dropout rate for clinical trials has long plagued researchers with evidence indicating that sometimes more than 30% of patient dropout during phase 3 clinical trials.(1) A substantial figure, this reality is detrimental not only to the studies themselves but also to the health and wellbeing of all those who may need but will not receive potentially life altering medical help for their conditions. Dr. Harsha Rajasimha, Founder and CEO of Jeeva Informatics, wants clinical trial sponsors and operators to understand what causes these high dropout rates and why it is so important to minimize them. Dr. Rajasimha feels greater remote accessibility for trial participants is key. "We want to make clinical trials universally accessible and more efficient."

Key Points: 
  • MANASSAS, Va. , Nov. 7, 2023 /PRNewswire-PRWeb/ -- The dropout rate for clinical trials has long plagued researchers with evidence indicating that sometimes more than 30% of patient dropout during phase 3 clinical trials.
  • "We want to make clinical trials universally accessible and more efficient."
  • Dr. Rajasimha says the one of the key goals of Sponsors should be to mitigate these risks of patient dropout in clinical trials.
  • "By accelerating the standardized adoption of decentralized clinical trials, Sponsors can achieve efficiency and accessibility for all patients who may seek them.

NEW REPORT: Public Health Departments Lack Funding for Hepatitis Surveillance Systems

Retrieved on: 
Friday, November 3, 2023
Associate, Infection, Korea Disease Control and Prevention Agency, Key finding attacks, Public health, White House, Hepatitis, Hepatitis C, Congress, Mortality, Viral hepatitis, Data collection, Local, HIV, Doctor of Philosophy, STD, Data, Data science, FTE, CDC, Gender identity, Disease, Risk, Health equity, Joe Biden, Emory, White, Public, Hepatitis B, D.C, Vaccine, Pharmaceutical industry, Epidemiology

~ HepVu and NASTAD, leading viral hepatitis organizations, release second annual assessment of viral surveillance practices across U.S. jurisdictions ~

Key Points: 
  • ~ HepVu and NASTAD, leading viral hepatitis organizations, release second annual assessment of viral surveillance practices across U.S. jurisdictions ~
    Washington, D.C. – Today, HepVu and NASTAD , leading viral hepatitis organizations, released a new report showing U.S. jurisdictions continue to lack funding and resources needed to effectively implement viral hepatitis surveillance programs.
  • A robust surveillance system allows the U.S. to monitor disease burden and disparities and mount an effective public health response to eliminate viral hepatitis in the U.S.
  • Robust viral hepatitis surveillance systems are critical to guide strategies for prevention and treatment of infections and to reduce viral hepatitis-related disparities and health inequities.
  • Prior to 2021, only 14 states received federal funding specifically for viral hepatitis surveillance.

PicnicHealth Announces Three New Advisors and Expands Expertise in Regulatory-ready Research

Retrieved on: 
Monday, November 6, 2023
Software, Research, Professional Services, Pharmaceutical, Data Management, Oncology, Consumer, Technology, Data Analytics, Science, Other Consumer, Biotechnology, Health, Food, Johns Hopkins University, Public health, Life, Registry, Merck, Brody, Acquisition, Regulation of tobacco by the U.S. Food and Drug Administration, Harvard University, Professional degrees of public health, Aetion, UnitedHealth Group, University of North Carolina at Pembroke, Cerner Enviza, Faculty of Management Studies – University of Delhi, Disease, Medicine, Health policy, University, Public, Harvard T.H. Chan School of Public Health, Cancer, Center for Drug Evaluation and Research, Health policy and management, Doctor of Philosophy, IQVIA, Pharmaceutical industry, Management, Psychology, Pharmacovigilance, New York University, Epidemiology

PicnicHealth , a leading patient-centered healthcare evidence generation company, appointed three advisors in clinical research design – Nancy Dreyer, Solomon Iyasu, and Jeremy Brody.

Key Points: 
  • PicnicHealth , a leading patient-centered healthcare evidence generation company, appointed three advisors in clinical research design – Nancy Dreyer, Solomon Iyasu, and Jeremy Brody.
  • These new advisors are joining PicnicHealth in an advisory capacity to support the company’s expansion into regulatory use cases.
  • Dr. Dreyer is an internationally recognized expert in the use of real-world evidence for regulatory purposes.
  • Dr. Dreyer holds a Ph.D. in epidemiology and Master of Public Health from the University of North Carolina, Chapel Hill.

Parkinson's Disease in 7 Major Markets Report 2023: Epidemiology, Disease Management, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Pipeline Analysis 2019-2029 - ResearchAndMarkets.com

Retrieved on: 
Friday, November 3, 2023
Health, General Health, Substantia nigra, Clinical trial, PD, Population Health Management, Therapy, Neuron, Parkinson, Protein, Brain, Lewy body, Encyclopedia of Major Marketing Strategies, Investment, Epidemiology, Parkinson's disease, Microsoft Excel, Pharmaceutical industry, Palladium, Marketing, Retail, Disease

The "Parkinson's Disease by Major Markets - Size, Trends and Drug Forecast including Epidemiology, Disease Management, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Pipeline Analysis to 2029" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Parkinson's Disease by Major Markets - Size, Trends and Drug Forecast including Epidemiology, Disease Management, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Pipeline Analysis to 2029" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This report encompasses the 7 Major Markets (US, France, Germany, Italy, Spain, UK, Japan) and includes an Excel-based forecast model for the Parkinson's Disease market, extending through the year 2029.
  • Anticipated growth in the PD market is driven by an increasingly aging population, complemented by the introduction of 14 pipeline products across the 7 Major Markets.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the PD therapeutics market.

Epidemiology and Genetics of Clonal Hematopoiesis, a Premalignant Hematopoietic Stem Cell Condition

Retrieved on: 
Monday, November 6, 2023
Stem cell, Genetic distance, Haematopoiesis, Peripheral artery disease, Epidemiology, Smoking, Clonal hematopoiesis, Lung cancer, Genetics, Mortality, Bone marrow, Health, Carcinoma, UK Biobank, CH, Emphysema, Genome, Disease, Risk, HSC, AMGN, Gene, Chronic obstructive pulmonary disease, Gene expression, Mutation, Cardiovascular disease, Vaccine, Amgen, Nature Genetics

Clonal hematopoiesis is a condition that arises when a single clonal lineage of hematopoietic stem cells (HSC) expands and becomes the source of a substantial proportion of mature blood cells.

Key Points: 
  • Clonal hematopoiesis is a condition that arises when a single clonal lineage of hematopoietic stem cells (HSC) expands and becomes the source of a substantial proportion of mature blood cells.
  • The study reaffirmed that clonal hematopoiesis is very common in the elderly, approaching 50% in people over 80 years old.
  • Clonal hematopoiesis has many of the hallmarks of a premalignant expansion of cell clones with a potential to become cancerous.
  • Overall, the study has provided substantial insights into the genetics and epidemiology of clonal hematopoiesis.

Epidemiology and Genetics of Clonal Hematopoiesis, a Premalignant Hematopoietic Stem Cell Condition

Retrieved on: 
Monday, November 6, 2023
Stem cell, Genetic distance, Haematopoiesis, Peripheral artery disease, Epidemiology, Smoking, Clonal hematopoiesis, Lung cancer, Genetics, Mortality, Bone marrow, Health, Carcinoma, UK Biobank, CH, Emphysema, Genome, Disease, Risk, HSC, AMGN, Gene, Chronic obstructive pulmonary disease, Gene expression, Mutation, Cardiovascular disease, Vaccine, Amgen, Nature Genetics

Clonal hematopoiesis is a condition that arises when a single clonal lineage of hematopoietic stem cells (HSC) expands and becomes the source of a substantial proportion of mature blood cells.

Key Points: 
  • Clonal hematopoiesis is a condition that arises when a single clonal lineage of hematopoietic stem cells (HSC) expands and becomes the source of a substantial proportion of mature blood cells.
  • The study reaffirmed that clonal hematopoiesis is very common in the elderly, approaching 50% in people over 80 years old.
  • Clonal hematopoiesis has many of the hallmarks of a premalignant expansion of cell clones with a potential to become cancerous.
  • Overall, the study has provided substantial insights into the genetics and epidemiology of clonal hematopoiesis.

The 2nd Boao International Conference on Real World Studies of Medical Products Held in Hainan

Retrieved on: 
Friday, November 3, 2023
National Medical Products Administration, Real World, RWD, NMPA, Economics, Conference, Merck, Research, Medicine, Pharmaceutical industry, Biostatistics, Epidemiology

HAIKOU, China, Nov. 3, 2023 /PRNewswire/ -- On 31st Oct., the 2nd Boao International Conference on Real World Studies of Medical Products, held in Boao, Hainan, was attended by nearly 1,000 participants from domestic and international pharmaceutical regulatory agencies, academic societies, industrial associations, pharmaceutical enterprises, etc.

Key Points: 
  • HAIKOU, China, Nov. 3, 2023 /PRNewswire/ -- On 31st Oct., the 2nd Boao International Conference on Real World Studies of Medical Products, held in Boao, Hainan, was attended by nearly 1,000 participants from domestic and international pharmaceutical regulatory agencies, academic societies, industrial associations, pharmaceutical enterprises, etc.
  • The conference featured a plenary session and eight sub-forums, and encompassed various fields related to international real-world research, and the scientific development of pharmaceutical product regulation.
  • According to Deputy Director of Biostatistics and Epidemiology, Real World Evidence Department, Merck, Germany, Real world study is a significant institutional innovation in the Hainan Free Trade Port.
  • "We learnt that four drugs and nine medical devices have been approved by National Medical Products Administration (NMPA) using Real World Data(RWD) from Hainan Boao Lecheng.

The 2nd Boao International Conference on Real World Studies of Medical Products Held in Hainan

Retrieved on: 
Friday, November 3, 2023
National Medical Products Administration, Real World, RWD, NMPA, Economics, Conference, Merck, Research, Multimedia, Medicine, Pharmaceutical industry, Biostatistics, Epidemiology

HAIKOU, China, Nov. 3, 2023 /PRNewswire/ -- On 31st Oct., the 2nd Boao International Conference on Real World Studies of Medical Products, held in Boao, Hainan, was attended by nearly 1,000 participants from domestic and international pharmaceutical regulatory agencies, academic societies, industrial associations, pharmaceutical enterprises, etc.

Key Points: 
  • HAIKOU, China, Nov. 3, 2023 /PRNewswire/ -- On 31st Oct., the 2nd Boao International Conference on Real World Studies of Medical Products, held in Boao, Hainan, was attended by nearly 1,000 participants from domestic and international pharmaceutical regulatory agencies, academic societies, industrial associations, pharmaceutical enterprises, etc.
  • The conference featured a plenary session and eight sub-forums, and encompassed various fields related to international real-world research, and the scientific development of pharmaceutical product regulation.
  • According to Deputy Director of Biostatistics and Epidemiology, Real World Evidence Department, Merck, Germany, Real world study is a significant institutional innovation in the Hainan Free Trade Port.
  • "We learnt that four drugs and nine medical devices have been approved by National Medical Products Administration (NMPA) using Real World Data(RWD) from Hainan Boao Lecheng.

Phigenics announces a peer-reviewed research paper on a large-scale field study that highlights deficiencies of ISO 11731 compared to the novel novel method, PVT VIABLE®

Retrieved on: 
Thursday, November 2, 2023
VBNC, Epidemiology, Monochloramine, PCR, PVT, Resuscitation, French Foreign Legion, Culture, ISO, Medical device, Surveying, Legionella, Legionnaires' disease

WARRENVILLE, Ill., Nov. 2, 2023 /PRNewswire-PRWeb/ -- Phigenics announces a peer-reviewed research paper, "Inaccuracies of the ISO 11731 Method for Environmental Validation of Legionella in Building Water Systems: Opportunities to Improve Sensitivity and Detect Viable but Non-Culturable Legionella," published in the "Clinical and Environmental Surveillance for the Prevention of Legionellosis" Issue of Microorganisms Journal.

Key Points: 
  • The data presented in this paper comprises a large-scale field study that highlights deficiencies of ISO 1173.
  • The study found a 21% discrepancy comparing the ISO 11731 spread plate method to the novel method, PVT VIABLE (Phigenics Validation Test- Viability Identification Assay by Legionella Enrichment.
  • The data presented in this paper comprises a large-scale field study that highlights deficiencies of ISO 11731.
  • Unlike ISO 11731, PVT VIABLE can detect VBNC Legionella, which has been shown to be pathogenic after resuscitation.

NIH Selects ICF for $31 Million in Biomedical and Digital Modernization Work

Retrieved on: 
Wednesday, November 1, 2023
ICFI, Epidemiology, National library, Health, United States National Library of Medicine, Human services, BPA, Maintenance, Data management, ClinicalTrials.gov, Caregiver, ICF, NLM, NIH, Public, Office of Inspector General, U.S. Department of Health and Human Services, Patient, Bangladesh Technical Education Board, Nursing

RESTON, Va., Nov. 1, 2023 /PRNewswire/ -- The National Institutes of Health (NIH) National Library of Medicine (NLM) recently awarded global consulting and technology services provider ICF (NASDAQ:ICFI) two agreements with a combined value of $31 million to provide biomedical and technical expertise, as well as data management and digital modernization services.

Key Points: 
  • The first agreement is a new multiple-award blanket purchase agreement (BPA) to collect, curate, and enhance access to critical biomedical and public health data.
  • ICF's efforts will improve data delivery to health researchers, professionals and the public so vital health decisions can quickly be made.
  • ICF has also been awarded five new task orders under the BPA with a combined value of $4 million to provide health expertise, systems maintenance and long-range planning support.
  • The second agreement is an 18-month, $27 million recompete contract for the operation, maintenance and modernization of ClinicalTrials.gov, a project ICF has supported since 2009.